Analysts assess the damage — and next steps — after Regeneron/Sanofi get slammed in court
A federal judge’s decision to order Regeneron and Sanofi to pull their PCSK9 drug Praluent from the market managed to stun some of the most grizzled observers of the biotech world.
These patent disputes are not at all unusual and are almost always settled with a share of the royalties when there’s a case to be made. And the court acknowledged that creating a monopoly here was not in the public’s best interest. But the judge came down squarely for Amgen, saying:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
